Quarterly report pursuant to Section 13 or 15(d)

Sponsored Research and Clinical Trial Agreements - Additional Information (Detail)

v3.10.0.1
Sponsored Research and Clinical Trial Agreements - Additional Information (Detail) - USD ($)
 3 Months Ended 9 Months Ended
Mar. 12, 2018
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Columbia University [Member]          
Research and Development Expense   $ 27,000   $ 100,000  
Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross $ 100,000        
University of Texas [Member]          
Research and Development Expense   100,000 $ 100,000 200,000 $ 0
University of North Carolina [Member]          
Research and Development Expense   200,000   600,000  
Checkpoint Therapeutics, Inc [Member]          
Research and Development Expense   0 $ 31,000 100,000 $ 500,000
Umass Sponsored Research Agreement [Member]          
Research and Development Expense   200,000   600,000  
Sponsor Research Agreement, Funding Commitment   800,000   800,000  
Payments For Research And Development Expenses       800,000  
UNC Sponsored Research Agreement [Member]          
Sponsor Research Agreement, Funding Commitment   2,300,000   2,300,000  
UNC Sponsored Research Agreement [Member] | Tamid [Member]          
Payments For Research And Development Expenses       800,000  
UPenn Sponsored Research Agreement [Member]          
Research and Development Expense   300,000   300,000  
Sponsor Research Agreement, Funding Commitment   $ 2,000,000   2,000,000  
Payments For Research And Development Expenses       $ 300,000